Articles by Melissa Badamo
The Foundation for Sickle Cell Disease Research will evaluate VAS-101 in a phase 1 clinical study.
The FDA granted orphan drug designation to rilzabrutinib for warm autoimmune hemolytic anemia and IgG4-related disease.
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a phase 1a/b study.
As the most common bleeding disorder, von Willebrand disease is found in up to 1% of the United States population.
PGK1 antibody levels in patients with recovered immuno-related pancytopenia were negatively correlated with platelet levels.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
CTD402 will enter a single-arm, open-label, phase 1b/2 trial aimed to optimize dosing and accelerate clinical development.
Thomas Martin, MD, presented data on CAR-T, bispecifics, and BCMAs in MM the National General Medical Oncology Summit.
Detectable MRD before HSCT is associated with worse survival in patients with MDS/MPN compared with undetectable MRD.
A phase 1 clinical trial is planned to test the safety and tolerability of AUTX-703 in patients with AML.
Adding ruxolitinib before, during, and after HSCT reduced the incidence of GVHD among patients with myelofibrosis.
Amneal has received FDA Approval for lenalidomide capsules in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strength.
The phase III MIRACLE trial is evaluating annamycin combined with cytarabine for relapsed or refractory AML.
Reni-cel led to hemoglobin normalization and increased fetal hemoglobin in patients with sickle cell disease.
Dapsone demonstrates efficacy and acceptable safety with low costs as treatment for pediatric ITP.
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
Patients receiving mitapivat showed a statistically significant hemoglobin response rate compared with placebo.
In a phase 1 trial presented at ASH 2024, clinical benefit was observed in 100% of patients receiving LYT-200 monotherapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.